ERAP1 and ankylosing spondylitis: ERAP1′s enzymatic activity can impact the risk of these diseases: when increased, the risk for ankylosing spondylitis and psoriasis is elevated, whereas when it is reduced, the risk decreases for Birdshot chorioretinopathy (BSCR) and Behçet’s disease.